250.59
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
BridgeBio’s Attruby Off To A Strong Start – But Alnylam Awaits - News & Insights
Ieq Capital LLC Acquires 34,613 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Vontobel Holding Ltd. Has $424,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update - MarketBeat
Rhumbline Advisers Sells 1,850 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Baillie Gifford & Co. Sells 846,741 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
BridgeBio: Strong Start For Attruby (NASDAQ:BBIO) - Seeking Alpha
Biotech Stocks Facing FDA Decision In March 2025 - RTTNews
Strategic Financial Concepts LLC Purchases Shares of 176,485 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $169,204.23 in Stock - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,561 Shares - MarketBeat
Jeffrey V. Poulton Sells 967 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 1,440 Shares - MarketBeat
Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates - MSN
Canaccord Genuity Group Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Asset Management One Co. Ltd. - MarketBeat
Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight - GlobeNewswire Inc.
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Scotiabank Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Earnings Results - MarketBeat
Alnylam Delivers a Big Q4 Earnings Beat - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript - Insider Monkey
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Alnylam Pharma: Hold Rating Due to Stable Financials and Uncertain Pipeline Prospects - TipRanks
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN
Antisense Oligonucleotides Market to Witness Significant - openPR
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals - MSN
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Alnylam Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Van ECK Associates Corp Purchases 10,419 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Savant Capital LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion - MSN
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC - MarketBeat
Learn to Evaluate (ALNY) using the Charts - Stock Traders Daily
Royal Bank of Canada Reiterates "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam Earnings: Strong Patient Uptake Drives Growth; Anticipating Approval of Amvuttra for ATTR-CM - Morningstar
Embrace the competition from China, says Maraganore - BioCentury
RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating - Marketscreener.com
Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlig - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Has $67.46 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Mirae Asset Global Investments Co. Ltd. Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam: Q4 Earnings Snapshot - mySA
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Alnylam: Waiting For Regulatory Updates In March (NASDAQ:ALNY) - Seeking Alpha
Reflections From Biotech Leader John Maraganore - News & Insights
Alnylam Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
大文字化:
|
ボリューム (24 時間):